UNITAID’s Market Approach in HIV Diagnostics


Published on

Presentation at the IAS 2011 conference on 18 July 2011 by Brenda Waning, UNITAID.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

UNITAID’s Market Approach in HIV Diagnostics

  1. 1. UNITAID’s Market Approach inHIV Diagnostics<br />Brenda Waning<br />International AIDS Society <br />18 July, 2011<br />Rome<br />
  2. 2. Presentation Outline<br /><ul><li> Overview of UNITAID
  3. 3. Description of UNITAID’s market approach to improve public health
  4. 4. Summary of UNITAID’s current and planned activities in the area of HIV diagnostics</li></li></ul><li>UNITAID: a WHO Partnership moving markets<br /><ul><li> Est. 2006: Innovative finance mechanism based largely on air tax levies from north & south
  5. 5. Geneva-based </li></ul>secretariat: no in-country offices – work with partners<br /><ul><li> Work exclusively through markets to improve access to medicines, diagnostics and preventative items for HIV/AIDS, tuberculosis, and malaria</li></ul>Partners<br />Working towards the common goal of expanding access to health<br />
  6. 6. UNITAID Goal <br />UNITAID aims to promote “healthy”, dynamic market conditions whereby manufacturers have incentives to invest and innovate, while at the same time supply quality public health products at sustainable, affordable prices and in acceptable formulations that enable the maximum number of people to access them. <br />
  7. 7. How UNITAID intervenes <br />UNITAID’s role depends upon the particular circumstances in a given market:<br /><ul><li>Market catalyst: identifying and facilitating adoption and uptake of new and/or superior public health products;
  8. 8. Market creator: providing incentives for manufacturers to produce otherwise unattractive products with low demand that yield little profit but substantial public health benefit to those in need; and
  9. 9. Market “fixer”: addressing severe market inefficiencies (e.g. grossly inaccurate demand forecasts and excessive transaction costs) that contribute to low access to quality-assured public health products.</li></li></ul><li>UNITAID Market impact framework<br />
  10. 10. UNITAID Market impact framework<br />UNITAID Intervention example: 2nd line ARV market<br />Partners: Clinton Health Access Initiative (CHAI), <br />WHO Prequalification Programme for Medicines<br />
  11. 11. UNITAID current & planned activities in HIV diagnostics (1))<br /><ul><li> Landscape analyses
  12. 12. map the landscape (disease, technology, market) for diagnostics across the 3 diseases
  13. 13. update every 6 months
  14. 14. internal value - inform priorities, decision making
  15. 15. external value: public good to other organizations
  16. 16. Call for letters of intent (and then proposals) for projects to increase access to diagnostics in the 3 disease areas
  17. 17. expected launch: last week of July 2011
  18. 18. To be posted on website: www.unitaid.eu</li></li></ul><li>HIV Diagnostics Landscape<br />Released 1 June<br />
  19. 19. UNITAID current & planned activities in HIV diagnostics (2)<br /><ul><li> Create mechanisms to compare potential projects against UNITAID prioritization criteria:
  20. 20. Market impact
  21. 21. Public health impact
  22. 22. Innovation
  23. 23. Value for money
  24. 24. Provide all inputs (landscapes, prioritization analyses) to UNITAID technical & decision-making bodies
  25. 25. Continue dialogue with other organizations
  26. 26. this session: dissemination & feedback</li></li></ul><li>Thank you<br />Contact Information:<br /> Brenda Waning<br /> Coordinator, Market Dynamics<br /> UNITAID<br /> Email: waningb@who.int<br />